IDENTIFYING REAL-WORLD DATA FOR OBSERVATIONAL STUDIES- A SYSTEMATIC APPROACH

Author(s)

Smoyer-Tomic KE1, Young KC1, Winchester C2
1Oxford PharmaGenesis™ Inc, Newtown, PA, USA, 2Oxford PharmaGenesis™ Ltd, Oxford, UK

OBJECTIVES: Real-world evidence informs product development, pricing, and reimbursement as well as patient care. An ongoing challenge, however, is in identifying and accessing the best available evidence to address a given research question. Our objective was to develop a systematic methodology to identify observational data sources for specific needs and to test it in both common and rare conditions in a range of therapeutic areas. METHODS: Systematic literature and Web searches, supplemented with email and telephone contact with data owners, were used to identify and characterize data sources suitable for use in 6 observational research programs spanning oncology, cardiology, and respiratory medicine. Data were captured and project-specific evaluation criteria applied regarding: study population; target geographies; type of clinical, diagnostic, and healthcare data required; length of follow up; and ability to identify patients across data sources. Data sources best meeting program objectives were recommended.  RESULTS: Over 14,000 references were screened across 6 separate studies. Of these, 4.5% to 8.6% were relevant to each study and were reviewed further. Direct contact with data owners was often needed to clarify whether inpatient and outpatient drug utilization, laboratory and imaging results, clinical assessments, healthcare utilization, patient-reported outcomes, and mortality data were available. Detailed characterization of the data sources identified by the systematic search reduced their number by 150–300-fold. This generated a manageable number of data sources (4–17 per study) to address specific research questions, including for prevalent cardiac conditions as well as a rare respiratory sub-population, in target geographies. CONCLUSIONS: The approach was effective in identifying accessible, relevant, and high-quality data for both rare and more prevalent conditions. A systematic understanding of real-world evidence has helped to guide observational research programs in diverse therapeutic areas with specialized data requirements.

Conference/Value in Health Info

2014-05, ISPOR 2014, Palais des Congres de Montreal

Value in Health, Vol. 17, No. 3 (May 2014)

Code

PRM48

Topic

Real World Data & Information Systems

Topic Subcategory

Reproducibility & Replicability

Disease

Multiple Diseases

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×